Compare CubeSmart (CUBE) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs Cytokinetics Inc — how do they compare? CubeSmart trades at $37.57 (market cap $8.45B), while Cytokinetics Inc trades at $62.73 (market cap $8.62B). The key difference: CubeSmart and Cytokinetics Inc are close in size by market cap, and CubeSmart pays a 5.65% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CubeSmart for 89 Days and Cytokinetics Inc for 19 Days on average.
| CUBE | CYTK | |
|---|---|---|
Market Cap | $8.45B | $8.62B |
Volume | 2,879,532 | 2,594,626 |
Sector | Real Estate | Health |
52-Week High | $42.50 | $87.26 |
52-Week Low | $35.36 | $54.76 |
Typical Hold Time | 89 Days | 19 Days |
Enterprise Value | $11.97B | $8.72B |
Dividend Yield | 5.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CUBE trades at $37.23, down 1.4% on the day, with a bearish technical signal and mixed earnings history including a Q2 2026 FFO miss. The company maintains strong profitability with a 29.41% net income margin and a 5.4% dividend yield, but faces headwinds from moderating revenue growth and high leverage.
The outlook is cautiously optimistic with a consensus price target of $44.00, though risks include elevated debt levels and sector oversupply. Upside hinges on operational improvements and a return to earnings growth in H2 2026 as guided.
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
